Key Insights into Hims & Hers Health's Earnings Report for 2025
Hims & Hers Health's Upcoming Earnings Announcement
Hims & Hers Health (NYSE: HIMS) is preparing to release its quarterly earnings report soon, creating significant anticipation among investors eager to see if the company will surpass earnings estimates. Analysts are forecasting earnings per share (EPS) of $0.10 for the upcoming report.
Historical Performance Overview
In the previous quarter, it was reported that the company's EPS missed expectations by $0.04, which directly resulted in a 12.36% drop in share price the following day. This trend highlights the potential volatility in Hims & Hers Health's stock when earnings do not align with investor expectations.
Earnings Performance Metrics
Looking at the past few quarters, the following figures underscore the company’s performance and stock volatility:
Quarterly EPS Estimations and Results:
Investors are closely monitoring the EPS estimates for the next quarter, given the previous discrepancies that led to notable price movements.
Recent Stock Performance
As of the end of October, Hims & Hers Health's shares were trading at approximately $44.06, reflecting a remarkable increase of 120.13% over the past year. Such strong returns likely contribute to a positive outlook from long-term investors, particularly as the company approaches its upcoming earnings release.
Market Sentiment and Analyst Ratings
Understanding market sentiment regarding Hims & Hers Health is crucial for prospective investors. Currently, analysts hold a consensus rating of "Buy" for Hims & Hers Health. Notably, the average one-year price target is estimated at $52.50, suggesting a potential upside of 19.16% from the current price.
Comparison with Industry Peers
Comparing Hims & Hers Health with its peers—Chemed, BrightSpring Health, and RadNet—provides valuable insights into its market positioning:
- Chemed is also rated as a "Buy" with a staggering potential upside of 1199.36% based on an average one-year price target of $572.50.
- BrightSpring Health has a "Buy" recommendation, yet it carries a downside risk with an average price target at $35.14.
- RadNet shares the "Buy" designation with a projected upside of 77.78% from its current price level of $78.33.
Overview of Peer Metrics
A quick look at essential metrics demonstrates how Hims & Hers Health compares to others in the industry:
Key Performance Indicators:
| Company | Consensus Rating | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Hims & Hers Health | Buy | 72.61% | $416.20M | 7.65% |
| Chemed | Buy | 0.99% | $184.69M | 5.65% |
| BrightSpring Health | Buy | 28.17% | $392.01M | 3.14% |
| RadNet | Buy | 8.38% | $69.14M | 1.58% |
What to Know About Hims & Hers Health
Founded in 2017, Hims & Hers Health operates as a telehealth service that simplifies access to essential healthcare products and services. The platform not only addresses issues like erectile dysfunction and hair loss but also offers treatments for skin care, mental health, and weight management. With over two million subscribers across the U.S. and select European markets, the company is expanding rapidly while accommodating a direct-to-consumer payment model that bypasses insurance systems.
Financial Performance Analysis
Market Capitalization and Growth: The market cap of Hims & Hers Health is currently below the industry average, indicating room for potential growth. The company’s impressive revenue growth rate of 72.61% illustrates its strong market presence.
Strong Margins: The firm's net margin of 7.8% demonstrates excellent cost control and robust financial health, positioning it as a leader among its industry counterparts.
Return on Equity (ROE): The 7.65% ROE signals effective capital use, although its debt-to-equity ratio of 1.86 suggests caution might be needed when considering investment due to potential financial risks.
Frequently Asked Questions
What are Hims & Hers Health's earnings predictions?
Analysts expect the company to report earnings per share of $0.10 in the upcoming quarterly report.
How has Hims & Hers Health's stock performed recently?
The stock rose by 120.13% over the last year, making it a solid performer in the market.
What do analysts think about Hims & Hers Health?
Analysts generally have a "Buy" rating, with a potential upside price target of $52.50.
How does Hims & Hers compare to its competitors?
It leads in revenue growth and gross profit margin compared to peers like Chemed and BrightSpring Health.
What services does Hims & Hers Health provide?
The company offers telehealth services for conditions including erectile dysfunction, hair loss, and mental health, among others.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.